Event dossier

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

1 report1 sourceMar 27, 2026, 11:43 AM
FilterCNBC
Clustered coverageCNBC
Coverage timeline1
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

CNBCMar 27, 2026, 11:43 AM

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.

Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.